2026-06-14T03:40:07Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/181962024-11-29T23:13:27Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Kamoun, Aurélie author de Reyniès, Aurélien author Allory, Yves author Sjödahl, Gottfrid author Robertson, A Gordon author Seiler, Roland author Hoadley, Katherine A author Groeneveld, Clarice S author Al-Ahmadie, Hikmat author Choi, Woonyoung author Castro, Mauro A A author Fontugne, Jacqueline author Eriksson, Pontus author Mo, Qianxing author Kardos, Jordan author Zlotta, Alexandre author Hartmann, Arndt author Dinney, Colin P author Bellmunt, Joaquim author Powles, Thomas author Malats, Núria author Chan, Keith S author Kim, William Y author McConkey, David J author Black, Peter C author Dyrskjøt, Lars author Höglund, Mattias author Lerner, Seth P author Real Arribas, Francisco author Radvanyi, François author 2020-04 BACKGROUND Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application. OBJECTIVE To achieve an international consensus on MIBC molecular subtypes that reconciles the published classification schemes. DESIGN, SETTING, AND PARTICIPANTS We used 1750 MIBC transcriptomic profiles from 16 published datasets and two additional cohorts. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS We performed a network-based analysis of six independent MIBC classification systems to identify a consensus set of molecular classes. Association with survival was assessed using multivariable Cox models. RESULTS AND LIMITATIONS We report the results of an international effort to reach a consensus on MIBC molecular subtypes. We identified a consensus set of six molecular classes: luminal papillary (24%), luminal nonspecified (8%), luminal unstable (15%), stroma-rich (15%), basal/squamous (35%), and neuroendocrine-like (3%). These consensus classes differ regarding underlying oncogenic mechanisms, infiltration by immune and stromal cells, and histological and clinical characteristics, including outcomes. We provide a single-sample classifier that assigns a consensus class label to a tumor sample's transcriptome. Limitations of the work are retrospective clinical data collection and a lack of complete information regarding patient treatment. CONCLUSIONS This consensus system offers a robust framework that will enable testing and validation of predictive biomarkers in future prospective clinical trials. PATIENT SUMMARY Bladder cancers are heterogeneous at the molecular level, and scientists have proposed several classifications into sets of molecular classes. While these classifications may be useful to stratify patients for prognosis or response to treatment, a consensus classification would facilitate the clinical use of molecular classes. Conducted by multidisciplinary expert teams in the field, this study proposes such a consensus and provides a tool for applying the consensus classification in the clinical setting. Eur Urol . 2020 ;77(4):420-433 10.1016/j.eururo.2019.09.006 1873-7560 European urology 31563503 http://hdl.handle.net/20.500.12105/18196 A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.